Nauman Chaudhry, MD
Retina Specialist · Waterford, CTNPI 1770513715
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 43.4% of the total. Reporting peaked in 2022 at $1,783 and has fallen 92.9% since, to $126 in 2025.
Across 14 payments — averaging $283.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$2K
- Genentech, Inc.$2K
- Ocular Therapeutix, Inc.$304
- Hoffmann-la Roche Limited$178
- Alimera Sciences, Inc.$37
- Johnson & Johnson$27
- plus $19 from 1 others
Across 2,154 payments — averaging $3393.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2.8M
- Genentech, Inc.$2.1M
- Bayer$1.3M
- Ocular Therapeutix, Inc.$881K
- Amgen$107K
- Apellis Pharmaceuticals, Inc.$65K
- plus $111K from 6 others
What the payments were for
- Consulting fees$1,68042%
- Speaking & faculty fees$1,51238%
- Food & beverage$75419%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 3 | $1,720 |
| Genentech, Inc. | 1 | $1,680 |
| Ocular Therapeutix, Inc. | 5 | $304 |
| Hoffmann-la Roche Limited | 2 | $178 |
| Alimera Sciences, Inc. | 1 | $37 |
| Johnson & Johnson | 1 | $27 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 27 | $9,360 |
| Prednisolone Acetate | 174 | $8,167 |
| Bromfenac Sodium | 26 | $3,954 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $3,231 |
| Ofloxacin | 102 | $1,353 |
| Ketorolac Tromethamine | 38 | $1,195 |
| ErythromycinErythromycin Base | 51 | $527 |
| Latanoprost | 17 | $144 |
| Timolol Maleate | 15 | $62 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Waterford
- Juner Colina BiscottoWaterford$1K
- Scott WalterManchester$312K
- Greg BudoffManchester$5K
- Armand DaccacheDanbury$3K
- Stephanie SuginWaterbury$2K
- Richard ScartozziDanbury$2K
- Craig SklarWaterbury$2K
- Tomasz WiraszkaWaterbury$2K
- Vincent ReppucciDanbury$1K
- Jennifer NadelmannNew Haven$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.